Adding peptide therapy to a medical practice starts with a defined medical service, not a broad peptide catalog. The practice needs an indication-based formulary, independently licensed prescribers, a state-compliant pharmacy pathway, documented consent, and advertising that distinguishes FDA-approved products from compounded medication. Every prescribing decision remains with the treating clinician.
What should a practice offer first?
A practice should begin with a narrow clinical category and a documented formulary rather than advertise “peptide therapy” as one treatment. The category might be weight management, diabetes care, or another service supported by an FDA-approved indication and the clinician’s evaluation of medical need.
The phrase can cover very different products, regulatory pathways, and claims. Approval of an active ingredient does not approve every formulation, use, marketing statement, or compounded version. Before the first patient encounter, build an indication matrix that records:
- Product name and active ingredient
- FDA-approved indication
- Current FDA labeling
- Relevant contraindications and boxed warnings
- Whether the proposed use is on-label or off-label
- Commercial availability
- Whether a compounded pathway is legally available
- Required follow-up and documentation
Which FDA-approved peptide medications can a practice consider?
FDA-approved peptide-related options identified in FDA materials include semaglutide products such as Ozempic and Rybelsus for type 2 diabetes and Wegovy for chronic weight management and certain cardiovascular-risk reduction indications. Tirzepatide products include Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Liraglutide products include Victoza for type 2 diabetes and Saxenda for chronic weight management.
FDA materials also identify other approved peptide products, including exenatide, dulaglutide, lixisenatide, glucagon, calcitonin, teriparatide, and pegcetacoplan products. The practice should verify the current label for each product instead of relying on a general category description.
For example, the Zepbound prescribing information includes a contraindication for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It also states that coadministration with other tirzepatide-containing products or GLP-1 receptor agonists is not recommended. That kind of label-specific information belongs in the clinical review process and medication-specific consent—not in a generalized sales page.
Are compounded peptides FDA-approved?
No. Compounded drugs are not FDA-approved, and FDA does not evaluate their safety, effectiveness, or quality before marketing. FDA recommends using an FDA-approved drug when it is available and medically appropriate.
A 503A pharmacy generally compounds for an individual patient pursuant to a valid prescription and faces restrictions on routinely producing products that are essentially copies of commercially available drugs. A 503B outsourcing facility operates under additional requirements, including restrictions involving copies of FDA-approved products and bulk drug substances.
The regulatory position can change as shortage determinations and FDA actions change. FDA proposed on April 30, 2026, to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk-drug list, stating that it found no clinical need for outsourcing facilities to compound those substances from bulk ingredients. The proposal’s final status should be checked before launch and again during ongoing operations.
A practice should maintain separate approved-product and compounded-product pathways. Do not automatically substitute a compound when an approved product is unavailable, and do not describe a compounded product as the same as, equivalent to, or a generic version of a branded product.
For a deeper operational review, use the FDA peptide compounding rules for telehealth clinics as a related planning resource.
How do I set up a peptide therapy program for physicians?
A peptide therapy program for physicians needs clinical governance, state-by-state prescriber verification, pharmacy controls, consent documents, and a follow-up workflow. The practice owner can organize the business infrastructure, but cannot take over patient-specific diagnosis, medical necessity, medication selection, or prescribing.
The setup sequence
- 1Choose the clinical category. Define whether the service is weight management, diabetes care, or another specific medical offering. Avoid launching with an unlimited peptide catalog.
- 2Approve the formulary. Record the product, indication, label, contraindications, availability, and whether a proposed use is on-label or off-label.
- 3Separate approved and compounded pathways. Use distinct documentation, consent language, pharmacy review, and substitution controls for compounded medication.
- 4Verify prescriber authority. Confirm each clinician’s license, scope of practice, independent prescribing authority, and any supervision, collaboration, delegation, or written-agreement requirements in the patient’s state.
- 5Review the entity structure. Establish who owns the professional medical entity, who owns the brand and nonclinical systems, and how the management relationship avoids control of clinical decisions.
- 6Onboard the pharmacy. Verify the pharmacy’s license, 503A or 503B status, shipment authority, prescription process, labeling, storage, recalls, and adverse-event workflow.
- 7Build clinical protocols. Define the evaluation, medication review, objective data or testing when clinically indicated, follow-up, refill review, escalation, and discontinuation processes.
- 8Create consent and disclosures. Explain FDA approval status, compounding status, alternatives, risks, telehealth limitations, costs, and follow-up responsibilities.
- 9Review advertising. Substantiate health claims before publication and remove guarantees, unsupported testimonials, and ambiguous “FDA-approved” language.
- 10Audit the program. Recheck FDA labeling, shortage status, pharmacy status, state rules, adverse events, and marketing claims on a scheduled basis.
The FDA Drug Shortages Database should be checked at the time of prescribing and dispensing because shortage status can change. A shortage does not by itself authorize every compounded pathway.
What prescriber and pharmacy structure does a telehealth program need?
The practice needs a real clinician-patient encounter with an adequate history, medication review, relevant examination or objective data, risk assessment, informed consent, and follow-up plan. A questionnaire-only intake should not be treated as a sufficient medical evaluation.
The operating checklist should identify who evaluates the patient, who handles follow-up and refill requests, who reviews adverse events, and who makes discontinuation decisions. It should also document which clinicians may prescribe independently and where collaboration, supervision, or delegation applies.
The pharmacy agreement should address:
| Operating question | What the practice should document |
|---|---|
| Which pharmacy pathway? | 503A or 503B status and applicable requirements |
| Where can it dispense? | License and authority to ship to each destination state |
| How are prescriptions handled? | Transmission, refill, transfer, and discontinuation procedures |
| What happens during a recall? | Communication, replacement, reporting, and escalation process |
| Who handles adverse events? | Pharmacy and practice responsibilities, documentation, and routing |
| Is compounding involved? | Patient-specific rationale, disclosures, and no automatic substitution |
The practice should not call a pharmacy “FDA-approved” merely because the pharmacy is licensed or registered. FDA approval applies to particular drug products, not generally to pharmacies or compounded medications.
Most commonly discussed peptide products are not controlled substances. The DEA’s telemedicine flexibilities for controlled substances were extended through December 31, 2026, but that extension does not remove state telehealth, licensure, standard-of-care, or prescribing obligations for a peptide program.
What consent forms are needed for telehealth peptide therapy?
A well-designed program uses coordinated documents: general medical informed consent, telehealth consent, medication-specific consent, a compounding disclosure when applicable, financial and pharmacy disclosures, privacy and communications consent, and follow-up or emergency-care instructions.
Medication-specific consent should state:
- Whether the product is FDA-approved
- The approved indication, when relevant
- Whether the proposed use is off-label
- Whether the product is compounded
- That compounded medication is not FDA-approved
- Known risks, contraindications, and alternatives
- Monitoring and follow-up expectations
- How refills and medication changes are handled
- Who makes the clinical decision
- How adverse events are reported
State expectations vary. California’s Medical Board states that telehealth must meet the same standard of care as in-person care and that telehealth consent must be obtained and documented. New York official telehealth standards used by the Office of Mental Health illustrate a more detailed consent model that includes documented consent, discussion of telehealth advantages and disadvantages, the right to receive in-person services, and information allowing license verification. Those New York standards should not automatically be applied to every medical practice, but they show why state-specific review matters.
How should a practice describe peptide therapy in advertising?
Describe the service as a clinician-led medical evaluation and treatment program for eligible patients, using FDA-approved medications when appropriate and considering compounded medication only when legally permissible and medically necessary. Do not market “peptides” as a guaranteed outcome, universal wellness solution, or shortcut to a specific result.
Avoid claims such as:
- Guaranteed weight loss
- No side effects
- Anti-aging peptide therapy
- Safe muscle building
- FDA-approved compounded peptides
- The same as a named brand product
- Disease reversal
- Works for everyone
FTC guidance requires health advertising to be truthful, not misleading, and supported by competent and reliable scientific evidence. Substantiation must exist before a claim is disseminated; testimonials and individual experiences do not replace scientific support.
The page should clearly distinguish FDA-approved products from compounded products, approved indications from off-label uses, medical care from wellness coaching, clinician fees from medication costs, and practice services from pharmacy services.
For owners adding a weight-management service, the medical weight loss program compliance checklist can help organize state, clinical, pharmacy, and advertising reviews.
Which state issues should a national practice review?
Rules vary by state. A national peptide therapy telehealth program should not assume that one ownership, examination, consent, or prescribing model works everywhere.
- California: The Medical Board states that professional medical corporations must be owned by one or more California-licensed physicians and provides guidance on corporate-practice restrictions. Telehealth must meet the same standard of care as in-person care, and consent must be obtained and documented. A nonphysician entrepreneur generally needs a carefully structured management relationship rather than direct ownership or control of the professional medical entity.
- Texas: Texas law subjects telemedicine to the same standard of care as equivalent in-person services and permits synchronous audiovisual care and certain asynchronous methods when the practitioner has relevant clinical information and provides appropriate follow-up. The Texas Medical Board describes physician involvement, input, and approval in medical decision-making policies as part of its corporate-practice discussion. Flexible telehealth modalities do not authorize a questionnaire-only prescribing model or management-company control of patient-specific decisions.
- New York: New York Department of Health guidance addresses restrictions on unauthorized corporate practice. The applicable entity, ownership, clinician availability, and consent structure should receive state-specific review before launch. New York’s official telehealth standards used by the Office of Mental Health also demonstrate that some programs expect detailed documented consent and information about in-person alternatives.
- Florida and Oregon: The materials reviewed for this article did not verify all requested ownership, supervision, examination, scope, and peptide-advertising rules for these states. A launch should therefore treat those issues as unresolved and review current statutes and professional-board requirements before accepting patients there.
A founder should have healthcare counsel, the responsible clinical leader, and the relevant professional board requirements review the entity, prescribing, pharmacy, consent, and marketing model before launch. This article is an educational business framework, not legal or medical advice.
What should founders compare in a peptide telehealth platform?
When evaluating a peptide therapy telehealth program setup, compare operational ownership rather than promotional claims. Ask each platform:
- Can the workflow support state-based clinician and patient-location controls?
- Are clinical decisions reserved to independently licensed clinicians?
- Can approved and compounded pathways be documented separately?
- Does the system support consent, medication review, follow-up, adverse-event routing, and audit records?
- Can the brand distinguish practice services from pharmacy services?
- Can the owner update labels, shortage checks, state rules, and advertising approvals?
- Does the platform support a professional entity and management-company structure without controlling clinical judgment?
MDLaunchr is one infrastructure option in this category. Its platform can run the business infrastructure and branded workflow, while independently licensed clinicians make the clinical decisions. It is not a pharmacy, regulator, law firm, or treating clinician, and platform support does not replace state-specific legal or clinical review.
Final launch checklist
Before launch, confirm that the practice has:
- A narrow clinical service definition
- A current product and indication matrix
- Label and contraindication review
- Separate approved and compounded workflows
- Verified clinician licenses and prescribing authority
- A reviewed professional entity and management structure
- Pharmacy license, status, and shipment checks
- Telehealth and medication-specific consent
- Follow-up and adverse-event procedures
- FTC-compliant advertising substantiation
- State-specific reviews for every launch market
- A recurring audit for labels, shortages, pharmacy status, rules, and claims
That structure lets an existing practice add a peptide therapy program as a controlled medical service instead of a loosely defined product menu. To compare one white-label infrastructure option, see the peptide therapy program setup.
Related reading: the full guide this article belongs to.
Written and reviewed by MDLaunchr's clinical and compliance team. We build white-label telehealth infrastructure for founders, creators, and healthcare operators—covering providers, pharmacy, technology, and compliance.
This article is for general informational and educational purposes only and is not medical, legal, or regulatory advice. It does not create a provider-patient relationship and should not be used to diagnose or treat any condition. Telehealth and compounding regulations vary by state and change over time—consult qualified legal, clinical, and compliance professionals before launching or operating a telehealth program.
Frequently asked questions
How do I add peptide therapy to my practice?
Start with a defined clinical category, an indication-based formulary, licensed prescribers, a compliant pharmacy pathway, consent documents, state reviews, and advertising approval before accepting patients.
Can my practice prescribe compounded tirzepatide?
A practice may need a patient-specific medical rationale and a pharmacy pathway that satisfies current federal and state requirements; compounded medication is not FDA-approved, and availability and legality can change with FDA shortage and compounding actions.
How do I add semaglutide to my practice?
Evaluate the relevant FDA-approved products and indications first, then verify current labeling, availability, clinician authority, pharmacy operations, consent, and state telehealth requirements.
What pharmacy can compound peptides for my clinic?
The appropriate pharmacy depends on the product, patient-specific need, pharmacy status, state authority, and current compounding rules; verify whether it is a 503A pharmacy or 503B outsourcing facility.
Do I need a medical director for a peptide therapy clinic?
The answer depends on the entity structure, clinician type, scope of practice, supervision or collaboration rules, and target states; qualified clinicians must retain control of medical decisions.
Can an NP prescribe peptide therapy in my state?
An NP’s authority depends on the state, medication, scope of practice, and applicable independent-practice, supervision, collaboration, or delegation rules.
Are compounded peptides FDA-approved?
No, compounded drugs are not FDA-approved, and FDA does not evaluate their safety, effectiveness, or quality before marketing.
What consent forms are needed for telehealth peptide therapy?
The program should coordinate medical, telehealth, medication-specific, compounding, financial, pharmacy, privacy, and follow-up disclosures, with exact requirements reviewed for each state and practice type.
Can a management company choose the medication for a patient?
A management company should not control diagnosis, medical necessity, medication selection, or patient-specific prescribing where state corporate-practice rules restrict lay control.
How should a practice market peptide therapy?
Market a defined clinician-led medical service with truthful, substantiated claims and clearly distinguish FDA-approved products, compounded products, indications, off-label use, pharmacy services, and practice services.
What is the next step for adding a branded program?
Map the formulary, entity, clinician, pharmacy, state, consent, and advertising requirements, then see the peptide therapy program setup to evaluate a white-label telehealth infrastructure option.
- U.S. Food & Drug Administration — Compounding and FDA Questions and AnswersCompounding When Drugs Are Fdas Drug Shortages ListFDA Proposes Exclude Semaglutide Tirzepatide and Liraglutide 503B Bulks List
- Federal Trade Commission — Health Products Compliance Guidance
- California State Government — Telehealth